Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating mental health integration in PrEP programs to reduce HIV incidence among US gay and bisexual men: a network modeling study.

BMC health services research·2026
Same author

Substance use and mental health before versus during COVID-19 pandemic among persons who inject drugs with HCV infection history-the HERO study.

Harm reduction journal·2026
Same author

Achieving SVR is associated with long term reduced hazardous alcohol use for people who inject drugs receiving HCV treatment: The HERO study.

Drug and alcohol dependence·2026
Same author

Exploring the intersections of sexual stigma, poverty and mental health in HIV-negative gay, bisexual and other men who have sex with men in the United States.

PLOS mental health·2026
Same author

Impact of Social Drivers of Health, Self-Efficacy, and Substance Use on COVID-19 Preventative Behaviors Among Persons Who Inject Drugs with Hepatitis C: The HERO Study.

International journal of environmental research and public health·2026
Same author

Pharmacy staff willingness to establish pre-exposure prophylaxis-based collaborative practice agreements in the Southeast United States.

Journal of the American Pharmacists Association : JAPhA·2025

Related Experiment Video

Updated: May 16, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Current management options for latent tuberculosis: a review.

Brianna L Norton1, David P Holland

  • 1Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA.

Infection and Drug Resistance
|December 11, 2012
PubMed
Summary

New tuberculosis treatments using rifamycins improve patient adherence and are cost-effective compared to standard isoniazid therapy. These shorter regimens offer a better approach to treating latent tuberculosis infection globally.

Keywords:
interferon-gamma release assayisoniazidrifampinrifapentinetuberculin skin test

Related Experiment Videos

Last Updated: May 16, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Area of Science:

  • Public Health
  • Infectious Diseases
  • Pharmacology

Background:

  • Tuberculosis (TB) is a leading infectious cause of death, with latent infection affecting one-third of the global population.
  • Latent TB infection treatment is crucial for TB control, particularly in low-to medium-incidence regions.
  • Isoniazid monotherapy, the long-standing standard, suffers from poor patient adherence.

Purpose of the Study:

  • To review current latent tuberculosis infection (LTBI) therapies.
  • To evaluate the toxicities associated with different LTBI treatment regimens.
  • To provide an economic comparison of available LTBI treatment options.

Main Methods:

  • Literature review of existing therapies for latent tuberculosis infection.
  • Analysis of reported treatment completion rates and adverse events.
  • Economic evaluation comparing standard and novel regimens.

Main Results:

  • Shorter-course regimens incorporating rifamycins demonstrate improved treatment completion rates over isoniazid monotherapy.
  • Rifamycin-based regimens are found to be cost-saving compared to the standard isoniazid approach.
  • Review includes assessment of toxicities for various LTBI treatment options.

Conclusions:

  • Novel, shorter-course rifamycin-based regimens represent an advancement in latent tuberculosis infection treatment.
  • These regimens offer improved adherence and cost-effectiveness, addressing limitations of traditional isoniazid therapy.
  • Updated treatment guidelines should consider these more effective and economical options for global TB control efforts.